Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 33.47% is 29% below its 5-year average of 47.17%, near the low end of its 5-year range (33.43%–52.74%).
28.04% below its 12-month average of 46.51%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 49.46%.
GROSS MARGIN
33.47%
GROSS MARGIN AVG TTM
46.51%
GROSS MARGIN AVG 3Y
46.56%
GROSS MARGIN AVG 5Y
47.17%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-28.04%
CURRENT VS 3Y AVG
-28.11%
CURRENT VS 5Y AVG
-29.04%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.82%
median of 649 covered companies
CURRENT VS SECTOR MEDIAN
-18.01%
vs the sector median at left
Health Catalyst, Inc.
Market Cap
$129.43M
Gross Margin
33.47%
TTM Avg
46.51%
3Y Avg
46.56%
5Y Avg
47.17%
Market Cap
$132.31M
Gross Margin
3.67%
TTM Avg
16.70%
3Y Avg
18.97%
5Y Avg
8.54%
Market Cap
$124.48M
Gross Margin
58.78%
TTM Avg
29.39%
3Y Avg
14.70%
5Y Avg
9.80%
Market Cap
$123.66M
Gross Margin
-62.76%
TTM Avg
-61.84%
3Y Avg
-230.63%
5Y Avg
-163.28%
Market Cap
$136.43M
Gross Margin
61.99%
TTM Avg
62.83%
3Y Avg
59.84%
5Y Avg
59.96%
Market Cap
$121.92M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Health Catalyst, Inc. (HCAT) | $129.43M | 33.47% | 46.51% | 46.56% | 47.17% |
| Entera Bio Ltd. (ENTX)vs › | $128.40M | 0.00% | 2.48% | -4.54% | 5.72% |
| Organigram Global Inc. (OGI)vs › | $132.31M | 3.67% | 16.70% | 18.97% | 8.54% |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $124.48M | 58.78% | 29.39% | 14.70% | 9.80% |
| Freenome, Inc. (FRNM)vs › | $135.17M | N/A | N/A | N/A | N/A |
| LifeMD, Inc. (LFMD)vs › | $135.17M | 85.91% | 84.21% | 85.09% | 82.87% |
| Cibus, Inc. (CBUS)vs › | $123.66M | -62.76% | -61.84% | -230.63% | -163.28% |
| KORU Medical Systems, Inc. (KRMD)vs › | $136.43M | 61.99% | 62.83% | 59.84% | 59.96% |
| enGene Holdings Inc. (ENGN)vs › | $121.92M | 0.00% | 0.00% | 0.00% | 0.00% |
| TuHURA Biosciences, Inc. (HURA)vs › | $121.00M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
33.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 49.46% |
| 2026-03-31 | 33.43% |
| 2025-12-31 | 52.74% |
| 2025-09-30 | 49.55% |
| 2025-06-30 | 47.37% |
| 2025-03-31 | 45.63% |
| 2024-12-31 | 43.58% |
| 2024-09-30 | 44.58% |
| 2024-06-30 | 47.22% |
| 2024-03-31 | 48.45% |
| 2023-12-31 | 40.63% |
| 2023-09-30 | 43.36% |
| 2023-06-30 | 46.13% |
| 2023-03-31 | 48.15% |
| 2022-12-31 | 44.90% |
| 2022-09-30 | 46.84% |
| 2022-06-30 | 51.00% |
| 2022-03-31 | 50.07% |
| 2021-12-31 | 47.65% |
| 2021-09-30 | 46.41% |
| 2021-06-30 | 49.60% |
| 2021-03-31 | 51.05% |
| 2020-12-31 | 50.21% |
| 2020-09-30 | 48.40% |
| 2020-06-30 | 46.53% |
| 2020-03-31 | 46.65% |
| 2019-12-31 | 50.17% |
| 2019-09-30 | 52.74% |
| 2019-06-30 | 51.88% |
| 2019-03-31 | 50.80% |
| 2018-12-31 | 48.10% |
| 2018-09-30 | 48.29% |
| 2018-06-30 | 45.55% |
| 2018-03-31 | 43.73% |
